Abstract
Evaluation of: Icheva V, Kayser S, Wolff D et al. Adoptive transfer of Epstein-Barr virus (EBV) nuclear antigen 1-specific T cells as treatment for EBV reactivation and lymphoproliferative disorders after allogeneic stem-cell transplantation. J. Clin. Oncol. 31(1), 39-48 (2013). Adoptive transfer of donor-derived EBV-specific T cells is an effective strategy for the prevention and treatment of EBV-associated post-transplant lymphoproliferative disease (PTLD). However, the time-consuming process of EBV-specific T-cell generation using standard protocols has limited their broader use. Ex vivo IFN-γ capture assay is an attractive alternative for the rapid isolation of EBV-specific T cells. In the present study, Icheva et al. employ this method to rapidly isolate clinical-grade T cells that are specific for EBNA1. Adoptive transfer of EBNA1-specific T cells was safe and resulted in clinical benefit in 7 out of 10 patients with EBV-viremia and/or PTLD. Thus, T-cell therapy targeting a single EBV antigen, EBNA1, which is critical for EBV episome maintenance, may be sufficient for EBV-PTLD therapy in hematopoietic stem cells transplantation recipients.